CARSGEN-B (02171): Preliminary Results of CT0596 Presented at 67th ASH Annual Meeting

Stock News12-08

CARSGEN-B (02171) announced that preliminary results of CT0596, an allogeneic BCMA-targeted CAR-T cell candidate, were presented at the 67th American Society of Hematology (ASH) Annual Meeting.

The initial findings from the CT0596 investigator-initiated trial (IIT) were showcased in a poster presentation on December 6, 2025 (5:30 PM–7:30 PM EST) under the title: *"A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma."*

CT0596 is a universal CAR-T cell therapy targeting BCMA, developed using CARSGEN-B’s proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for relapsed/refractory multiple myeloma (R/R MM) or plasma cell leukemia (PCL). Early data demonstrated favorable safety and encouraging efficacy signals, with CAR-T cell expansion observed across all predefined dose cohorts.

Beyond R/R MM, the company plans to explore CT0596’s potential in other plasma cell malignancies and autoimmune diseases driven by autoreactive plasma cells. An Investigational New Drug (IND) application for this candidate is expected to be submitted in the second half of 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152366512?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 08:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152366512","market":"sh","top_or_hot":-1,"title":"CARSGEN-B (02171): Preliminary Results of CT0596 Presented at 67th ASH Annual Meeting","media":"Stock News","content":"<p>CARSGEN-B (02171) announced that preliminary results of CT0596, an allogeneic BCMA-targeted CAR-T cell candidate, were presented at the 67th American Society of Hematology (ASH) Annual Meeting.</p>\n<p>The initial findings from the CT0596 investigator-initiated trial (IIT) were showcased in a poster presentation on December 6, 2025 (5:30 PM–7:30 PM EST) under the title: *\"A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma.\"*</p>\n<p>CT0596 is a universal CAR-T cell therapy targeting BCMA, developed using CARSGEN-B’s proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for relapsed/refractory multiple myeloma (R/R MM) or plasma cell leukemia (PCL). Early data demonstrated favorable safety and encouraging efficacy signals, with CAR-T cell expansion observed across all predefined dose cohorts.</p>\n<p>Beyond R/R MM, the company plans to explore CT0596’s potential in other plasma cell malignancies and autoimmune diseases driven by autoreactive plasma cells. An Investigational New Drug (IND) application for this candidate is expected to be submitted in the second half of 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARSGEN-B (02171): Preliminary Results of CT0596 Presented at 67th ASH Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARSGEN-B (02171): Preliminary Results of CT0596 Presented at 67th ASH Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 08:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARSGEN-B (02171) announced that preliminary results of CT0596, an allogeneic BCMA-targeted CAR-T cell candidate, were presented at the 67th American Society of Hematology (ASH) Annual Meeting.</p>\n<p>The initial findings from the CT0596 investigator-initiated trial (IIT) were showcased in a poster presentation on December 6, 2025 (5:30 PM–7:30 PM EST) under the title: *\"A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma.\"*</p>\n<p>CT0596 is a universal CAR-T cell therapy targeting BCMA, developed using CARSGEN-B’s proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for relapsed/refractory multiple myeloma (R/R MM) or plasma cell leukemia (PCL). Early data demonstrated favorable safety and encouraging efficacy signals, with CAR-T cell expansion observed across all predefined dose cohorts.</p>\n<p>Beyond R/R MM, the company plans to explore CT0596’s potential in other plasma cell malignancies and autoimmune diseases driven by autoreactive plasma cells. An Investigational New Drug (IND) application for this candidate is expected to be submitted in the second half of 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1152366512","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152366512","pubTimestamp":1765152734,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CARSGEN-B (02171) announced that preliminary results of CT0596, an allogeneic BCMA-targeted CAR-T cell candidate, were presented at the 67th American Society of Hematology (ASH) Annual Meeting. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B","BK1585":"昨日强势股","BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股"},"translate_title":"科济康-B(02171)：CT0596在第67届ASH年会上公布的初步结果","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"CARSGEN-B (02171) announced that preliminary results of CT0596, an allogeneic BCMA-targeted CAR-T cell candidate, were presented at the 67th American Society of Hematology (ASH) Annual Meeting.\nThe initial findings from the CT0596 investigator-initiated trial (IIT) were showcased in a poster presentation on December 6, 2025 (5:30 PM–7:30 PM EST) under the title: *\"A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma.\"*\nCT0596 is a universal CAR-T cell therapy targeting BCMA, developed using CARSGEN-B’s proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for relapsed/refractory multiple myeloma (R/R MM) or plasma cell leukemia (PCL). Early data demonstrated favorable safety and encouraging efficacy signals, with CAR-T cell expansion observed across all predefined dose cohorts.\nBeyond R/R MM, the company plans to explore CT0596’s potential in other plasma cell malignancies and autoimmune diseases driven by autoreactive plasma cells. An Investigational New Drug (IND) application for this candidate is expected to be submitted in the second half of 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152366512","isCrawlerRequest":true}